International Journal of ADVANCED RESEARCH & INNOVATIONS

Volume 14, Issue-12
December, 2024, P16
ISSN: 2319-9253

PRECISION CANCER INTELLIGENCE: LEVERAGING FOUNDATION MODELS, DIGITAL TWINS, AND MULTIMODAL LEARNING FOR CLINICAL TRANSLATION

[#1]**Dr. MohanaIyer**, Professor, Department of Pharmacology,
Sri DevarajUrs Medical College, Kolar, India
Mohanaiyer80@gmail.com

[#2] **Dr. Pradeep Joshi**, Associate Professor, Department of Biochemistry,
Sri DevarajUrs Medical College, Kolar, India
Pradeepjoshi55@gmail.com

[#3] **Dr. Aditi Shah**, Assistant Professor, Department of Community Medicine,
Sri DevarajUrs Medical College, Kolar, India
Aditishah71@gmail.com

Abstract: Precision cancer intelligence is emerging as a transformative paradigm in modern oncology through the convergence of foundation artificial intelligence (AI) models, digital twins, multimodal learning, and translational clinical intelligence. Conventional oncology frequently relies on fragmented diagnostic modalities and isolated interpretation of molecular, imaging, pathological, and clinical information, thereby limiting comprehensive understanding of the dynamic biological complexity of cancer. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, and generative artificial intelligence have enabled unified analysis of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, and longitudinal clinical outcomes. These intelligent computational ecosystems support early cancer detection, biomarker discovery, molecular characterization, prognostic prediction, therapeutic optimization, immunotherapy selection, digital twin simulation, adaptive disease monitoring, and evidence-based clinical decision support. Emerging technologies including multimodal large language models, federated learning, reinforcement learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen precision cancer intelligence by enabling collaborative, privacy-preserving, transparent, and continuously adaptive biomedical reasoning. Despite remarkable technological advances, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interpretability, interoperability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of precision cancer intelligence, emphasizing the convergence of foundation AI, digital twins, and multimodal learning for successful clinical translation and personalized cancer medicine.[1]

Keywords: *Precision oncology, Foundation models, Artificial intelligence, Digital twins, Multimodal learning, Computational oncology, Clinical intelligence, Personalized medicine, Multi-omics, Clinical translation.*

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are properly cited.

1. Introduction

Cancer is a highly dynamic biological disease characterized by continuous genomic evolution, epigenetic remodeling, immune adaptation, metabolic reprogramming, angiogenesis, tissue remodeling, and intricate interactions among malignant cells, stromal components, immune populations, and host physiology. These

Paper Available at: *www.ijarai.com*
DOI : https://doi.org/10.65713/ijaraiv14i1216

Volume 14, Issue-12
December, 2024, P16
ISSN: 2319-9253

interconnected biological processes evolve throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon computational systems capable of integrating heterogeneous biomedical information across multiple biological scales.[2]

Modern healthcare generates unprecedented quantities of biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, physician documentation, electronic health records, and patient-reported outcomes. Although each modality contributes valuable biological insight, isolated interpretation frequently overlooks systems-level relationships governing disease progression, therapeutic response, resistance mechanisms, and long-term clinical outcomes.[3]

Artificial intelligence has emerged as a transformative computational technology capable of integrating these heterogeneous biomedical datasets into unified patient-centered representations. Foundation AI models provide generalized biomedical reasoning, digital twins create continuously evolving virtual patients, and multimodal learning enables adaptive fusion of complementary biomedical modalities.

The convergence of these technologies establishes precision cancer intelligence as a transformative computational framework capable of accelerating clinical translation and personalized oncology.[4]

2. Evolution of Precision Cancer Intelligence

Computational oncology has evolved from conventional statistical analyses toward intelligent biomedical ecosystems capable of continuously learning from multimodal healthcare data. Early machine learning approaches primarily relied upon handcrafted feature engineering and task-specific predictive algorithms developed for isolated diagnostic or prognostic applications. Although these systems demonstrated clinical value, they remained constrained by fragmented biomedical information, limited adaptability, and narrow generalizability.[5]

Deep learning substantially advanced computational oncology through automated representation learning from radiological imaging, digital pathology, genomic sequencing, and electronic health records. Transformer architectures subsequently revolutionized biomedical artificial intelligence by enabling generalized contextual learning across heterogeneous biomedical modalities.

Foundation AI models have now transformed oncology through large-scale self-supervised pretraining capable of generating transferable biomedical knowledge applicable across diagnosis, prognosis, biomarker discovery, therapeutic prediction, disease monitoring, radiomics, pathomics, genomics, and intelligent clinical decision support.[6]

3. Principles of Foundation AI Models

Foundation AI models differ fundamentally from conventional artificial intelligence because they acquire generalized biomedical representations from massive multimodal datasets before specialization for individual oncology applications. Rather than learning isolated predictive tasks, these models develop transferable computational knowledge applicable across diagnosis, prognosis, molecular characterization, biomarker discovery, therapeutic optimization, disease monitoring, computational pathology, radiomics, immunotherapy, and clinical decision support.[7]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, and longitudinal clinical trajectories within unified computational embedding spaces.

Graph neural networks further characterize interactions among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, and clinical outcomes, thereby enabling systems-level

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1216

Volume 14, Issue-12
December, 2024, P16
ISSN: 2319-9253

computational reasoning supporting precision oncology.[8]

4. Computational Architecture

Modern precision cancer intelligence platforms consist of interconnected computational layers responsible for biomedical data acquisition, preprocessing, representation learning, multimodal fusion, adaptive learning, predictive analytics, digital twin simulation, and intelligent clinical decision support.[9]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, and synchronize temporal patient information.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, and longitudinal clinical trajectories. These unified computational representations support diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive learning, and clinical translation.[10]

5. Multimodal Learning and Biomedical Data Fusion

Multimodal learning forms the computational foundation of precision cancer intelligence by integrating complementary biomedical modalities into unified patient-specific representations. Radiological imaging provides anatomical and functional characterization of tumors, digital pathology reveals microscopic tissue architecture, and multi-omics technologies—including genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, and spatial biology—offer comprehensive molecular characterization of evolving cancer biology.[11]

Wearable biosensors continuously monitor physiological parameters including heart rate, sleep quality, physical activity, medication adherence, treatment-related symptoms, and quality-of-life indicators, while electronic health records contribute longitudinal clinical context extending across diagnosis, treatment, recurrence, and survivorship.

Artificial intelligence harmonizes these diverse biomedical modalities using multimodal transformers, graph neural networks, biological knowledge graphs, and cross-modal attention mechanisms capable of generating adaptive computational embeddings representing continuously evolving patient biology.[12]

6. Digital Twins for Precision Oncology

Digital twin technology represents one of the most transformative components of precision cancer intelligence by creating continuously evolving computational replicas of individual patients synchronized with their biological counterparts. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[13]

Unlike conventional predictive models, digital twins continuously update their computational representations as new biomedical information becomes available. These intelligent virtual patients enable clinicians to evaluate multiple therapeutic strategies before implementation, optimize treatment sequencing, anticipate mechanisms of therapeutic resistance, and personalize supportive care according to evolving patient biology.[14]

7. Clinical Intelligence Through Electronic Health Records

Electronic health records provide one of the richest longitudinal sources of clinical information available in modern oncology. Structured

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1216

Volume 14, Issue-12
December, 2024, P16
ISSN: 2319-9253

laboratory investigations, medication history, pathology reports, treatment timelines, physician documentation, hospitalizations, patient-reported outcomes, and survivorship information collectively provide comprehensive patient-level context extending beyond molecular diagnostics.[15]

Foundation AI models employ natural language processing, temporal transformers, and multimodal reasoning architectures to integrate structured and unstructured EHR data with radiological imaging, digital pathology, molecular biology, laboratory biomarkers, wearable monitoring, and physiological information into unified patient-specific computational representations.

These integrated clinical embeddings substantially improve prognostic prediction, recurrence surveillance, toxicity estimation, therapeutic optimization, survivorship management, and evidence-based clinical decision-making.[16]

8. Clinical Translation of Precision Cancer Intelligence

One of the primary objectives of precision cancer intelligence is successful translation of computational innovation into routine clinical practice. Foundation AI models bridge basic biomedical research and bedside oncology by integrating molecular discoveries, imaging biomarkers, pathological interpretation, laboratory investigations, electronic health records, and clinical guidelines into comprehensive decision-support ecosystems. These intelligent computational frameworks facilitate biomarker validation, therapeutic stratification, adaptive clinical trial enrollment, precision surgery, individualized radiation planning, personalized systemic therapy, and longitudinal survivorship management while improving efficiency and consistency across multidisciplinary oncology workflows.[17][18]

9. Personalized Therapeutic Decision-Making

One of the most clinically significant applications of precision cancer intelligence is individualized therapeutic optimization through comprehensive integration of molecular biology, imaging phenotypes, histopathological characteristics, laboratory biomarkers, wearable physiological monitoring, medication history, and longitudinal clinical trajectories. Foundation AI models continuously predict responsiveness to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations while adapting therapeutic recommendations according to evolving patient biology, treatment response, toxicity profiles, and real-world clinical outcomes. These adaptive computational systems establish a comprehensive framework for clinically translatable precision oncology capable of improving patient outcomes across the entire cancer care continuum.[19][20]

10. Intelligent Clinical Decision Support

Precision cancer intelligence provides the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Rather than interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, foundation AI models synthesize these diverse biomedical information sources into unified computational representations supporting multidisciplinary oncology practice.[21]

Interactive clinical dashboards generate individualized diagnostic summaries, multimodal biomarker analyses, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, and survival predictions while facilitating collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, and computational scientists. These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce fragmentation of biomedical information, and promote evidence-based personalized cancer management throughout the cancer care continuum.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1216

Volume 14, Issue-12
December, 2024, P16
ISSN: 2319-9253

11. Continuous Learning and Adaptive Precision Oncology

A defining characteristic of precision cancer intelligence is its ability to continuously evolve as new biomedical information becomes available. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout the patient's clinical journey.[22]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes therapeutic recommendations through iterative evaluation of treatment outcomes. Agentic AI systems further coordinate evidence retrieval, diagnostic reasoning, workflow automation, treatment planning, and longitudinal disease surveillance with minimal manual intervention.

This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of supporting real-time personalized precision medicine.

12. Federated Foundation Model Ecosystems

Development of highly generalizable precision cancer intelligence platforms requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, treatment protocols, and patient populations. Federated learning enables collaborative development of foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[23]

Participating healthcare institutions independently train local models using radiological imaging, digital pathology, genomics, transcriptomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, and generalizability across diverse healthcare environments.

Federated precision oncology ecosystems therefore establish international computational oncology networks capable of accelerating scientific discovery, improving equitable access to precision medicine, and supporting global cancer research while maintaining responsible biomedical data stewardship.

13. Explainability, Validation, and Ethical Governance

Successful implementation of precision cancer intelligence requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations identifying the imaging, molecular, pathological, physiological, and clinical variables contributing to predictive outputs.[24]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, and continuous post-deployment surveillance to ensure trustworthy integration of intelligent computational systems into routine oncology practice.

14. Emerging Technologies Driving Clinical Translation

The future of precision cancer intelligence will be shaped by the convergence of multimodal foundation models, multimodal large language

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1216

Volume 14, Issue-12
December, 2024, P16
ISSN: 2319-9253

models, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, liquid biopsy, quantum computing, robotics, Internet of Medical Things (IoMT), cloud-native healthcare infrastructure, and autonomous clinical reasoning systems.[25]

These emerging technologies will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes into unified computational ecosystems capable of autonomous reasoning, adaptive therapeutic optimization, intelligent clinical trial matching, precision prevention, and personalized survivorship management.

This technological convergence is expected to accelerate translation of computational discoveries into routine oncology practice while improving healthcare efficiency and patient outcomes.

15. Future Perspectives

Future precision cancer intelligence ecosystems will progressively evolve beyond isolated decision-support tools toward comprehensive autonomous healthcare platforms capable of continuously modeling individual patient biology throughout diagnosis, treatment, recurrence, survivorship, and long-term follow-up.[26]

Digital twins will increasingly simulate alternative therapeutic pathways, foundation AI models will continuously incorporate newly published biomedical evidence, multimodal learning systems will integrate previously inaccessible biological modalities, and autonomous clinical agents will coordinate diagnostic workflows, multidisciplinary communication, patient education, clinical documentation, and precision treatment planning.

These integrated computational ecosystems are expected to support predictive, preventive, personalized, participatory, and precision oncology on an unprecedented global scale.

16. Discussion

Precision cancer intelligence represents one of the most significant paradigm shifts in modern computational oncology by integrating foundation AI, multimodal learning, digital twins, molecular biology, imaging intelligence, computational pathology, and longitudinal clinical reasoning into unified computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional artificial intelligence systems developed for isolated predictive tasks, these intelligent frameworks simultaneously analyze molecular biology, tissue architecture, radiological imaging, laboratory biomarkers, physiological monitoring, environmental influences, and longitudinal clinical trajectories to generate holistic representations of evolving cancer biology.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of integrated computational intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, precision cancer intelligence ecosystems are expected to become the central computational infrastructure supporting clinically translatable precision oncology worldwide.

17. Conclusion

Precision cancer intelligence is transforming personalized cancer medicine by converging foundation AI, digital twins, multimodal learning, radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and individualized

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1216

Volume 14, Issue-12
December, 2024, P16
ISSN: 2319-9253

clinical decision-making throughout the cancer care continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen these intelligent ecosystems, enabling increasingly accurate molecular characterization, predictive clinical intelligence, adaptive therapeutics, continuous disease surveillance, and continuously personalized oncology care.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of precision cancer intelligence. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) 'Enhancing Precision Oncology Through Multimodal Data Integration', Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
3. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
4. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
5. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
6. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
7. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
8. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
9. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
10. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
11. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
12. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
13. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
14. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
15. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1216

16. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
17. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
18. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
19. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
20. 20. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
21. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
22. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
23. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
24. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
25. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
26. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
27. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
28. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14

Volume 14, Issue-12
December, 2024, P16
ISSN: 2319-9253

29. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
30. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

Paper Available at: ***www.ijarai.com***
DOI : https://doi.org/10.65713/ijaraiv14i1216